Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dermatology | 69 | 2024 | 918 | 20.640 |
Why?
|
Psoriasis | 10 | 2024 | 946 | 4.050 |
Why?
|
Skin Diseases | 13 | 2023 | 1095 | 3.650 |
Why?
|
Internship and Residency | 28 | 2024 | 5885 | 3.540 |
Why?
|
Skin Neoplasms | 21 | 2024 | 5809 | 2.980 |
Why?
|
Lupus Erythematosus, Discoid | 3 | 2024 | 61 | 2.190 |
Why?
|
Lupus Erythematosus, Cutaneous | 4 | 2023 | 73 | 2.190 |
Why?
|
Drug Eruptions | 4 | 2024 | 335 | 2.120 |
Why?
|
Pyoderma Gangrenosum | 3 | 2023 | 84 | 2.060 |
Why?
|
Skin Pigmentation | 5 | 2024 | 277 | 1.890 |
Why?
|
Vitiligo | 3 | 2024 | 96 | 1.770 |
Why?
|
Consumer Health Information | 3 | 2024 | 215 | 1.610 |
Why?
|
Career Choice | 7 | 2022 | 757 | 1.580 |
Why?
|
Schools, Medical | 6 | 2024 | 878 | 1.570 |
Why?
|
Hemochromatosis | 2 | 2023 | 174 | 1.510 |
Why?
|
Education, Medical, Undergraduate | 7 | 2024 | 1072 | 1.490 |
Why?
|
Pityriasis Rubra Pilaris | 2 | 2021 | 20 | 1.450 |
Why?
|
Melanoma | 8 | 2024 | 5694 | 1.420 |
Why?
|
Exanthema | 4 | 2024 | 503 | 1.420 |
Why?
|
Remote Consultation | 3 | 2021 | 237 | 1.380 |
Why?
|
Humans | 189 | 2024 | 761208 | 1.280 |
Why?
|
Education, Medical, Graduate | 8 | 2024 | 2374 | 1.260 |
Why?
|
Telemedicine | 8 | 2023 | 3051 | 1.240 |
Why?
|
Dermatomyositis | 2 | 2022 | 258 | 1.160 |
Why?
|
Skin Diseases, Genetic | 2 | 2024 | 49 | 1.100 |
Why?
|
Oncolytic Virotherapy | 2 | 2024 | 515 | 1.090 |
Why?
|
Clinical Clerkship | 3 | 2018 | 564 | 1.070 |
Why?
|
Acne Vulgaris | 2 | 2022 | 349 | 1.050 |
Why?
|
Documentation | 4 | 2021 | 900 | 1.020 |
Why?
|
United States | 45 | 2024 | 72339 | 0.960 |
Why?
|
Collagen Diseases | 1 | 2024 | 39 | 0.940 |
Why?
|
Lupus Erythematosus, Systemic | 4 | 2023 | 2157 | 0.920 |
Why?
|
Pruritus | 2 | 2024 | 378 | 0.900 |
Why?
|
Ecthyma | 1 | 2023 | 7 | 0.890 |
Why?
|
Spondylarthropathies | 1 | 2023 | 14 | 0.880 |
Why?
|
Anemia | 2 | 2023 | 1504 | 0.880 |
Why?
|
Hereditary Autoinflammatory Diseases | 1 | 2024 | 42 | 0.880 |
Why?
|
Hyperpigmentation | 2 | 2023 | 116 | 0.880 |
Why?
|
Hidradenitis Suppurativa | 2 | 2024 | 177 | 0.860 |
Why?
|
Comprehension | 3 | 2024 | 619 | 0.850 |
Why?
|
Skin | 9 | 2024 | 4473 | 0.840 |
Why?
|
Lichen Nitidus | 1 | 2022 | 4 | 0.840 |
Why?
|
Sunburn | 1 | 2024 | 156 | 0.840 |
Why?
|
Curriculum | 7 | 2024 | 3741 | 0.830 |
Why?
|
Supreme Court Decisions | 1 | 2024 | 133 | 0.820 |
Why?
|
Foot Diseases | 3 | 2021 | 148 | 0.820 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2023 | 85 | 0.820 |
Why?
|
Medicine, Traditional | 2 | 2021 | 88 | 0.810 |
Why?
|
Lasers, Gas | 1 | 2023 | 101 | 0.810 |
Why?
|
Burnout, Professional | 2 | 2021 | 703 | 0.800 |
Why?
|
Lymphoma, B-Cell | 2 | 2019 | 938 | 0.800 |
Why?
|
Investments | 2 | 2022 | 147 | 0.790 |
Why?
|
Urban Health Services | 2 | 2021 | 176 | 0.790 |
Why?
|
Students, Medical | 6 | 2024 | 1940 | 0.780 |
Why?
|
Artificial Intelligence | 4 | 2024 | 2576 | 0.770 |
Why?
|
Music Therapy | 1 | 2023 | 111 | 0.770 |
Why?
|
Personnel Selection | 2 | 2024 | 196 | 0.760 |
Why?
|
Dermatologic Agents | 3 | 2021 | 313 | 0.760 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2024 | 364 | 0.760 |
Why?
|
Lasers, Solid-State | 1 | 2023 | 176 | 0.760 |
Why?
|
Foreign Medical Graduates | 1 | 2022 | 77 | 0.750 |
Why?
|
Vulnerable Populations | 3 | 2021 | 706 | 0.750 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2024 | 1874 | 0.740 |
Why?
|
Sclerosis | 1 | 2021 | 210 | 0.740 |
Why?
|
Mohs Surgery | 1 | 2023 | 222 | 0.720 |
Why?
|
Music | 1 | 2023 | 245 | 0.700 |
Why?
|
Medically Underserved Area | 2 | 2022 | 254 | 0.700 |
Why?
|
Webcasts as Topic | 1 | 2020 | 21 | 0.690 |
Why?
|
Skin Diseases, Infectious | 1 | 2020 | 76 | 0.680 |
Why?
|
Mongolian Spot | 1 | 2019 | 3 | 0.670 |
Why?
|
Stevens-Johnson Syndrome | 3 | 2024 | 246 | 0.670 |
Why?
|
Erythema Multiforme | 1 | 2019 | 31 | 0.670 |
Why?
|
Paraneoplastic Syndromes | 2 | 2020 | 155 | 0.660 |
Why?
|
Cross-Sectional Studies | 16 | 2024 | 26071 | 0.650 |
Why?
|
Intestinal Neoplasms | 1 | 2021 | 315 | 0.640 |
Why?
|
HIV Seronegativity | 1 | 2019 | 211 | 0.630 |
Why?
|
Pseudomonas Infections | 1 | 2023 | 621 | 0.630 |
Why?
|
Calcitriol | 2 | 2021 | 295 | 0.630 |
Why?
|
Specialty Boards | 1 | 2020 | 235 | 0.630 |
Why?
|
Indians, North American | 1 | 2022 | 351 | 0.620 |
Why?
|
Interleukins | 1 | 2023 | 782 | 0.620 |
Why?
|
Referral and Consultation | 3 | 2020 | 3608 | 0.620 |
Why?
|
Hospitals, University | 1 | 2020 | 565 | 0.620 |
Why?
|
Immunologic Techniques | 1 | 2018 | 212 | 0.610 |
Why?
|
Immunoconjugates | 2 | 2024 | 963 | 0.600 |
Why?
|
Skin Diseases, Papulosquamous | 1 | 2017 | 17 | 0.590 |
Why?
|
Carcinoma, Basal Cell | 1 | 2023 | 557 | 0.590 |
Why?
|
Chronic Disease | 6 | 2023 | 9319 | 0.580 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2024 | 782 | 0.570 |
Why?
|
Private Practice | 1 | 2018 | 152 | 0.570 |
Why?
|
Edema | 1 | 2021 | 764 | 0.570 |
Why?
|
Hemangiosarcoma | 1 | 2019 | 215 | 0.570 |
Why?
|
Faculty, Medical | 4 | 2019 | 1205 | 0.560 |
Why?
|
Hair | 1 | 2020 | 498 | 0.560 |
Why?
|
Immunologic Factors | 3 | 2016 | 1589 | 0.560 |
Why?
|
Certification | 1 | 2020 | 418 | 0.560 |
Why?
|
Rural Health Services | 1 | 2021 | 384 | 0.560 |
Why?
|
Outpatients | 2 | 2021 | 1598 | 0.540 |
Why?
|
Allied Health Personnel | 1 | 2018 | 154 | 0.540 |
Why?
|
History, 18th Century | 4 | 2019 | 206 | 0.540 |
Why?
|
Sarcoma, Kaposi | 1 | 2019 | 374 | 0.540 |
Why?
|
Ambulatory Care Facilities | 2 | 2023 | 934 | 0.540 |
Why?
|
Delivery of Health Care | 4 | 2023 | 5333 | 0.530 |
Why?
|
Erythema | 1 | 2018 | 262 | 0.530 |
Why?
|
Eosinophilia | 1 | 2021 | 557 | 0.530 |
Why?
|
Computer Security | 1 | 2018 | 260 | 0.530 |
Why?
|
Cellulitis | 2 | 2015 | 208 | 0.530 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 465 | 0.520 |
Why?
|
Needlestick Injuries | 1 | 2016 | 71 | 0.510 |
Why?
|
Necrobiotic Xanthogranuloma | 1 | 2015 | 10 | 0.510 |
Why?
|
Cephalexin | 1 | 2015 | 37 | 0.500 |
Why?
|
Medical Staff, Hospital | 1 | 2019 | 601 | 0.500 |
Why?
|
Ketones | 1 | 2016 | 182 | 0.490 |
Why?
|
Carcinogens | 1 | 2017 | 452 | 0.490 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2023 | 940 | 0.490 |
Why?
|
Quality of Life | 6 | 2023 | 13367 | 0.490 |
Why?
|
Comorbidity | 3 | 2024 | 10516 | 0.490 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2015 | 61 | 0.490 |
Why?
|
Triamcinolone Acetonide | 1 | 2015 | 100 | 0.490 |
Why?
|
Pandemics | 8 | 2023 | 8663 | 0.480 |
Why?
|
Physicians, Primary Care | 2 | 2021 | 619 | 0.480 |
Why?
|
Renal Dialysis | 1 | 2024 | 1796 | 0.480 |
Why?
|
Geriatrics | 1 | 2019 | 387 | 0.480 |
Why?
|
Internet | 3 | 2024 | 3096 | 0.470 |
Why?
|
History, 19th Century | 4 | 2019 | 718 | 0.470 |
Why?
|
Miliaria | 1 | 2014 | 6 | 0.470 |
Why?
|
Bibliometrics | 1 | 2018 | 352 | 0.470 |
Why?
|
Male | 51 | 2024 | 360693 | 0.470 |
Why?
|
Salivary Gland Neoplasms | 1 | 2018 | 304 | 0.470 |
Why?
|
Bookbinding | 1 | 2014 | 1 | 0.460 |
Why?
|
Tanning | 1 | 2014 | 10 | 0.460 |
Why?
|
Neurodermatitis | 1 | 2014 | 8 | 0.460 |
Why?
|
Phototherapy | 3 | 2024 | 368 | 0.460 |
Why?
|
Garlic | 1 | 2014 | 28 | 0.460 |
Why?
|
Biomedical Research | 3 | 2020 | 3434 | 0.460 |
Why?
|
Euphorbia | 1 | 2013 | 1 | 0.450 |
Why?
|
Occlusive Dressings | 1 | 2014 | 52 | 0.450 |
Why?
|
Lichen Planus | 1 | 2014 | 70 | 0.450 |
Why?
|
Internal Medicine | 1 | 2021 | 1050 | 0.450 |
Why?
|
Arsenic | 1 | 2017 | 361 | 0.450 |
Why?
|
Physician's Role | 1 | 2020 | 920 | 0.450 |
Why?
|
Pharyngitis | 1 | 2015 | 220 | 0.450 |
Why?
|
Myelodysplastic Syndromes | 1 | 2024 | 1393 | 0.450 |
Why?
|
Hypopigmentation | 1 | 2013 | 43 | 0.440 |
Why?
|
Nose Diseases | 1 | 2014 | 79 | 0.440 |
Why?
|
Medical Informatics | 1 | 2020 | 733 | 0.430 |
Why?
|
Medicare | 7 | 2023 | 6773 | 0.430 |
Why?
|
Azithromycin | 1 | 2014 | 199 | 0.430 |
Why?
|
Plant Preparations | 1 | 2014 | 94 | 0.430 |
Why?
|
Exons | 1 | 2019 | 2380 | 0.430 |
Why?
|
Data Interpretation, Statistical | 1 | 2023 | 2691 | 0.430 |
Why?
|
Diabetic Ketoacidosis | 1 | 2016 | 253 | 0.420 |
Why?
|
Skin Diseases, Vascular | 1 | 2013 | 41 | 0.420 |
Why?
|
Natural Language Processing | 1 | 2022 | 1165 | 0.420 |
Why?
|
Burns, Chemical | 1 | 2014 | 123 | 0.420 |
Why?
|
Diterpenes | 1 | 2013 | 170 | 0.410 |
Why?
|
Patient Satisfaction | 3 | 2022 | 3453 | 0.410 |
Why?
|
Keratosis, Actinic | 1 | 2013 | 72 | 0.410 |
Why?
|
Radiotherapy | 2 | 2019 | 1499 | 0.410 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 686 | 0.410 |
Why?
|
Triage | 1 | 2019 | 985 | 0.400 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1052 | 0.400 |
Why?
|
Cytosine | 1 | 2013 | 212 | 0.400 |
Why?
|
Acute Disease | 4 | 2023 | 7226 | 0.400 |
Why?
|
Hospitalization | 6 | 2023 | 10707 | 0.400 |
Why?
|
Sex Characteristics | 1 | 2023 | 2640 | 0.400 |
Why?
|
Anti-Bacterial Agents | 4 | 2021 | 7407 | 0.400 |
Why?
|
Reimbursement Mechanisms | 1 | 2018 | 667 | 0.400 |
Why?
|
Radiation Injuries | 1 | 2019 | 1191 | 0.400 |
Why?
|
Bone Marrow Transplantation | 2 | 2019 | 2692 | 0.400 |
Why?
|
Physicians | 5 | 2022 | 4584 | 0.400 |
Why?
|
Inappropriate Prescribing | 1 | 2014 | 212 | 0.390 |
Why?
|
Neoplasms | 5 | 2023 | 22140 | 0.390 |
Why?
|
Periodicals as Topic | 2 | 2020 | 1463 | 0.390 |
Why?
|
Hand Dermatoses | 3 | 2017 | 62 | 0.390 |
Why?
|
Phytotherapy | 1 | 2014 | 296 | 0.390 |
Why?
|
Female | 43 | 2024 | 392544 | 0.380 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2013 | 264 | 0.380 |
Why?
|
Sodium Chloride | 1 | 2014 | 584 | 0.380 |
Why?
|
Homosexuality, Male | 1 | 2019 | 1336 | 0.380 |
Why?
|
Protein Kinase Inhibitors | 2 | 2018 | 5662 | 0.380 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2013 | 168 | 0.380 |
Why?
|
Health Status Disparities | 1 | 2023 | 1847 | 0.380 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3089 | 0.380 |
Why?
|
Middle Aged | 32 | 2024 | 220853 | 0.380 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2015 | 328 | 0.380 |
Why?
|
Physicians, Women | 1 | 2017 | 510 | 0.380 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2013 | 229 | 0.370 |
Why?
|
Vascular Diseases | 1 | 2019 | 1160 | 0.370 |
Why?
|
Tretinoin | 1 | 2014 | 517 | 0.370 |
Why?
|
Streptococcal Infections | 1 | 2015 | 617 | 0.370 |
Why?
|
Endothelium, Vascular | 2 | 2022 | 4420 | 0.370 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2015 | 668 | 0.360 |
Why?
|
Cultural Diversity | 3 | 2024 | 369 | 0.360 |
Why?
|
Crohn Disease | 1 | 2023 | 2278 | 0.360 |
Why?
|
Biological Products | 1 | 2020 | 915 | 0.360 |
Why?
|
Antibodies, Monoclonal | 2 | 2024 | 9187 | 0.350 |
Why?
|
Specialization | 1 | 2015 | 778 | 0.350 |
Why?
|
Diagnostic Errors | 2 | 2014 | 1265 | 0.350 |
Why?
|
Terminology as Topic | 1 | 2017 | 1528 | 0.350 |
Why?
|
Alopecia | 1 | 2014 | 412 | 0.340 |
Why?
|
Retrospective Studies | 17 | 2024 | 80674 | 0.340 |
Why?
|
Information Dissemination | 1 | 2018 | 1129 | 0.340 |
Why?
|
Plant Extracts | 1 | 2013 | 496 | 0.340 |
Why?
|
Influenza Vaccines | 1 | 2017 | 767 | 0.340 |
Why?
|
Probiotics | 1 | 2013 | 378 | 0.340 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2024 | 2254 | 0.330 |
Why?
|
Anus Neoplasms | 1 | 2013 | 330 | 0.330 |
Why?
|
Neurology | 1 | 2017 | 784 | 0.330 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2014 | 424 | 0.330 |
Why?
|
Vaccination | 2 | 2022 | 3369 | 0.330 |
Why?
|
Oligopeptides | 1 | 2015 | 1179 | 0.330 |
Why?
|
Hospitals, General | 1 | 2013 | 799 | 0.330 |
Why?
|
Aged | 23 | 2024 | 169288 | 0.320 |
Why?
|
Sepsis | 1 | 2023 | 2585 | 0.320 |
Why?
|
Leadership | 2 | 2021 | 1385 | 0.320 |
Why?
|
Health Policy | 2 | 2021 | 2679 | 0.320 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2018 | 1074 | 0.320 |
Why?
|
Vasculitis | 1 | 2013 | 522 | 0.320 |
Why?
|
Immunocompromised Host | 4 | 2023 | 858 | 0.320 |
Why?
|
Immunotherapy, Adoptive | 1 | 2018 | 1468 | 0.310 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5425 | 0.310 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2017 | 5666 | 0.310 |
Why?
|
Cicatrix | 1 | 2014 | 793 | 0.310 |
Why?
|
Mental Health | 1 | 2023 | 3251 | 0.310 |
Why?
|
Hematologic Neoplasms | 1 | 2020 | 1895 | 0.310 |
Why?
|
Sex Factors | 5 | 2021 | 10553 | 0.300 |
Why?
|
Administration, Topical | 3 | 2015 | 703 | 0.300 |
Why?
|
Medical Oncology | 1 | 2020 | 2320 | 0.300 |
Why?
|
Pyrazoles | 1 | 2018 | 2010 | 0.290 |
Why?
|
Pyrimidines | 3 | 2021 | 3027 | 0.290 |
Why?
|
Sarcoma | 1 | 2019 | 1800 | 0.290 |
Why?
|
Gastrointestinal Tract | 1 | 2013 | 834 | 0.290 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 709 | 0.290 |
Why?
|
Interviews as Topic | 1 | 2015 | 2697 | 0.290 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3354 | 0.290 |
Why?
|
Combined Modality Therapy | 5 | 2024 | 8519 | 0.290 |
Why?
|
Graft vs Host Disease | 3 | 2017 | 3025 | 0.280 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20982 | 0.280 |
Why?
|
Diarrhea | 1 | 2013 | 1316 | 0.280 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2020 | 4021 | 0.270 |
Why?
|
United States Department of Veterans Affairs | 1 | 2012 | 928 | 0.270 |
Why?
|
Hepatitis C, Chronic | 1 | 2015 | 1027 | 0.270 |
Why?
|
Interleukin-2 | 1 | 2013 | 1891 | 0.270 |
Why?
|
Adult | 24 | 2024 | 221119 | 0.270 |
Why?
|
Attitude of Health Personnel | 2 | 2019 | 3885 | 0.260 |
Why?
|
Authorship | 2 | 2020 | 284 | 0.260 |
Why?
|
Administration, Cutaneous | 2 | 2021 | 713 | 0.260 |
Why?
|
Diagnosis, Differential | 5 | 2022 | 12976 | 0.260 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1624 | 0.250 |
Why?
|
Case-Control Studies | 4 | 2024 | 22174 | 0.250 |
Why?
|
Psychiatry | 1 | 2017 | 1699 | 0.250 |
Why?
|
Health Expenditures | 1 | 2018 | 2362 | 0.250 |
Why?
|
RNA, Small Interfering | 1 | 2013 | 3412 | 0.230 |
Why?
|
Medicine | 3 | 2022 | 942 | 0.230 |
Why?
|
Efficiency, Organizational | 2 | 2019 | 695 | 0.230 |
Why?
|
Treatment Outcome | 11 | 2023 | 64681 | 0.230 |
Why?
|
Liver Neoplasms | 1 | 2020 | 4309 | 0.230 |
Why?
|
Enterovirus | 1 | 2024 | 67 | 0.230 |
Why?
|
Protective Clothing | 1 | 2024 | 103 | 0.220 |
Why?
|
Prostatectomy | 1 | 2012 | 1825 | 0.220 |
Why?
|
Immunotherapy | 3 | 2023 | 4642 | 0.220 |
Why?
|
Fellowships and Scholarships | 2 | 2023 | 1115 | 0.220 |
Why?
|
Sunscreening Agents | 1 | 2024 | 139 | 0.210 |
Why?
|
School Admission Criteria | 1 | 2024 | 107 | 0.210 |
Why?
|
Prurigo | 1 | 2023 | 25 | 0.210 |
Why?
|
Antineoplastic Agents | 4 | 2024 | 13632 | 0.210 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11733 | 0.210 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13385 | 0.200 |
Why?
|
Biopsy, Needle | 2 | 2020 | 1624 | 0.200 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2023 | 410 | 0.200 |
Why?
|
Clinical Trials as Topic | 2 | 2015 | 8003 | 0.200 |
Why?
|
Ointments | 1 | 2021 | 58 | 0.200 |
Why?
|
Simuliidae | 1 | 2021 | 5 | 0.190 |
Why?
|
Play and Playthings | 1 | 2021 | 85 | 0.190 |
Why?
|
Photography | 1 | 2024 | 532 | 0.190 |
Why?
|
Hair Removal | 1 | 2021 | 40 | 0.190 |
Why?
|
Confidence Intervals | 2 | 2018 | 2928 | 0.190 |
Why?
|
Nonprescription Drugs | 1 | 2022 | 118 | 0.180 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10203 | 0.180 |
Why?
|
Insect Bites and Stings | 1 | 2021 | 71 | 0.180 |
Why?
|
Postoperative Complications | 3 | 2021 | 15637 | 0.180 |
Why?
|
Isotretinoin | 1 | 2022 | 134 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5321 | 0.180 |
Why?
|
Teaching | 2 | 2020 | 1171 | 0.180 |
Why?
|
Oncolytic Viruses | 1 | 2024 | 344 | 0.180 |
Why?
|
Faculty | 2 | 2022 | 383 | 0.170 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 12159 | 0.170 |
Why?
|
Skin Care | 1 | 2020 | 56 | 0.170 |
Why?
|
Antigens, CD34 | 1 | 2022 | 655 | 0.170 |
Why?
|
Access to Information | 1 | 2023 | 316 | 0.170 |
Why?
|
Program Evaluation | 3 | 2019 | 2489 | 0.170 |
Why?
|
History, 20th Century | 2 | 2017 | 2765 | 0.160 |
Why?
|
Southeastern United States | 1 | 2019 | 91 | 0.160 |
Why?
|
Insurance | 1 | 2021 | 113 | 0.160 |
Why?
|
Hospitals, Special | 1 | 2019 | 90 | 0.160 |
Why?
|
Automation | 1 | 2021 | 585 | 0.160 |
Why?
|
Electronic Health Records | 4 | 2021 | 4822 | 0.160 |
Why?
|
Fatal Outcome | 2 | 2014 | 1838 | 0.160 |
Why?
|
Hyperplasia | 1 | 2022 | 1150 | 0.160 |
Why?
|
Information Seeking Behavior | 1 | 2020 | 116 | 0.160 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 380 | 0.160 |
Why?
|
Personal Autonomy | 1 | 2021 | 306 | 0.160 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2018 | 84 | 0.150 |
Why?
|
Physician Executives | 1 | 2019 | 134 | 0.150 |
Why?
|
Community-Institutional Relations | 1 | 2020 | 206 | 0.150 |
Why?
|
Prescriptions | 1 | 2021 | 386 | 0.150 |
Why?
|
Alopecia Areata | 1 | 2021 | 128 | 0.150 |
Why?
|
Creatinine | 1 | 2024 | 1897 | 0.150 |
Why?
|
Back | 1 | 2018 | 64 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2013 | 9278 | 0.150 |
Why?
|
Africa South of the Sahara | 1 | 2021 | 745 | 0.150 |
Why?
|
Arthritis, Rheumatoid | 1 | 2013 | 3753 | 0.150 |
Why?
|
Paris | 1 | 2017 | 41 | 0.150 |
Why?
|
Light | 1 | 2023 | 1348 | 0.150 |
Why?
|
Biomedical Technology | 1 | 2020 | 210 | 0.140 |
Why?
|
Personal Satisfaction | 1 | 2022 | 645 | 0.140 |
Why?
|
Syndrome | 1 | 2024 | 3271 | 0.140 |
Why?
|
Child | 7 | 2023 | 80152 | 0.140 |
Why?
|
Public Opinion | 1 | 2021 | 485 | 0.140 |
Why?
|
Scalp Dermatoses | 1 | 2017 | 44 | 0.140 |
Why?
|
Austria | 1 | 2017 | 206 | 0.140 |
Why?
|
Vaccines, Inactivated | 1 | 2017 | 178 | 0.140 |
Why?
|
Iatrogenic Disease | 1 | 2020 | 539 | 0.140 |
Why?
|
Arm | 1 | 2019 | 589 | 0.140 |
Why?
|
Dermatitis | 1 | 2018 | 202 | 0.130 |
Why?
|
Young Adult | 6 | 2024 | 59221 | 0.130 |
Why?
|
3-Hydroxybutyric Acid | 1 | 2016 | 72 | 0.130 |
Why?
|
Hospitals, Teaching | 1 | 2021 | 1155 | 0.130 |
Why?
|
Efficiency | 1 | 2019 | 476 | 0.130 |
Why?
|
Mutation | 4 | 2024 | 30002 | 0.130 |
Why?
|
England | 1 | 2017 | 526 | 0.130 |
Why?
|
Patient Education as Topic | 2 | 2023 | 2317 | 0.130 |
Why?
|
Antistreptolysin | 1 | 2015 | 6 | 0.130 |
Why?
|
Students, Dental | 2 | 2015 | 172 | 0.130 |
Why?
|
Calcifediol | 1 | 2017 | 160 | 0.130 |
Why?
|
Technology | 1 | 2018 | 294 | 0.130 |
Why?
|
Foot Dermatoses | 1 | 2016 | 47 | 0.130 |
Why?
|
Mentors | 1 | 2021 | 663 | 0.130 |
Why?
|
Databases as Topic | 1 | 2017 | 473 | 0.130 |
Why?
|
Data Collection | 2 | 2023 | 3320 | 0.130 |
Why?
|
Uncertainty | 1 | 2020 | 752 | 0.130 |
Why?
|
Antigens, CD19 | 1 | 2018 | 424 | 0.130 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1791 | 0.130 |
Why?
|
Pseudomonas aeruginosa | 1 | 2023 | 1272 | 0.120 |
Why?
|
Goals | 1 | 2020 | 710 | 0.120 |
Why?
|
Embolism, Cholesterol | 1 | 2015 | 32 | 0.120 |
Why?
|
Glomerular Filtration Rate | 1 | 2024 | 2182 | 0.120 |
Why?
|
Seasons | 1 | 2021 | 1518 | 0.120 |
Why?
|
Time Factors | 5 | 2020 | 39957 | 0.120 |
Why?
|
Clobetasol | 1 | 2015 | 33 | 0.120 |
Why?
|
Connective Tissue Diseases | 1 | 2018 | 285 | 0.120 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2015 | 42 | 0.120 |
Why?
|
Methylmethacrylate | 1 | 2014 | 39 | 0.120 |
Why?
|
Leg | 1 | 2019 | 1087 | 0.120 |
Why?
|
Inpatients | 2 | 2023 | 2545 | 0.120 |
Why?
|
Clostridium Infections | 1 | 2021 | 557 | 0.120 |
Why?
|
Facial Dermatoses | 1 | 2015 | 86 | 0.120 |
Why?
|
Publishing | 1 | 2021 | 832 | 0.120 |
Why?
|
Child, Preschool | 5 | 2023 | 42224 | 0.120 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15520 | 0.120 |
Why?
|
Naturopathy | 1 | 2014 | 13 | 0.120 |
Why?
|
Herpesvirus 1, Human | 1 | 2020 | 739 | 0.120 |
Why?
|
Social Class | 1 | 2023 | 1993 | 0.110 |
Why?
|
Blood Transfusion | 1 | 2021 | 1303 | 0.110 |
Why?
|
Facial Neoplasms | 1 | 2015 | 125 | 0.110 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 6304 | 0.110 |
Why?
|
Keratosis | 1 | 2014 | 79 | 0.110 |
Why?
|
Electrons | 1 | 2015 | 265 | 0.110 |
Why?
|
Massachusetts | 2 | 2019 | 8837 | 0.110 |
Why?
|
Dermoscopy | 1 | 2014 | 66 | 0.110 |
Why?
|
Models, Economic | 1 | 2018 | 714 | 0.110 |
Why?
|
Purpura | 1 | 2014 | 117 | 0.110 |
Why?
|
Blister | 1 | 2014 | 86 | 0.110 |
Why?
|
Leg Ulcer | 1 | 2014 | 71 | 0.110 |
Why?
|
Heterozygote | 1 | 2020 | 2778 | 0.110 |
Why?
|
Lower Extremity | 1 | 2021 | 1201 | 0.110 |
Why?
|
Piperidines | 2 | 2021 | 1656 | 0.110 |
Why?
|
Calciphylaxis | 1 | 2015 | 130 | 0.110 |
Why?
|
Carcinoid Tumor | 1 | 2015 | 225 | 0.110 |
Why?
|
Clinical Competence | 3 | 2024 | 4788 | 0.110 |
Why?
|
Staff Development | 1 | 2015 | 227 | 0.110 |
Why?
|
Educational Status | 2 | 2018 | 2510 | 0.110 |
Why?
|
Hair Color | 1 | 2013 | 131 | 0.110 |
Why?
|
Biopsy | 3 | 2014 | 6781 | 0.110 |
Why?
|
Sampling Studies | 1 | 2014 | 615 | 0.110 |
Why?
|
Ribavirin | 1 | 2015 | 394 | 0.100 |
Why?
|
Needs Assessment | 1 | 2019 | 1141 | 0.100 |
Why?
|
Hydroxyurea | 1 | 2014 | 284 | 0.100 |
Why?
|
Brain Neoplasms | 1 | 2014 | 9025 | 0.100 |
Why?
|
Granuloma | 1 | 2015 | 326 | 0.100 |
Why?
|
Fee-for-Service Plans | 1 | 2018 | 698 | 0.100 |
Why?
|
Mucormycosis | 1 | 2014 | 102 | 0.100 |
Why?
|
Diplopia | 1 | 2014 | 214 | 0.100 |
Why?
|
Hemianopsia | 1 | 2014 | 120 | 0.100 |
Why?
|
Dermatitis, Allergic Contact | 1 | 2014 | 111 | 0.100 |
Why?
|
Algorithms | 3 | 2022 | 14025 | 0.100 |
Why?
|
Education, Dental | 1 | 2015 | 219 | 0.100 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5493 | 0.100 |
Why?
|
Adenine | 1 | 2018 | 986 | 0.100 |
Why?
|
Polycythemia Vera | 1 | 2014 | 161 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3093 | 0.100 |
Why?
|
Allergy and Immunology | 1 | 2014 | 177 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3215 | 0.100 |
Why?
|
Health Behavior | 1 | 2024 | 2641 | 0.100 |
Why?
|
Necrosis | 2 | 2014 | 1610 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3881 | 0.100 |
Why?
|
Inflammation | 2 | 2023 | 10759 | 0.100 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1232 | 0.100 |
Why?
|
Students | 1 | 2022 | 1737 | 0.100 |
Why?
|
Kidney Failure, Chronic | 1 | 2024 | 2478 | 0.100 |
Why?
|
Gait Disorders, Neurologic | 1 | 2014 | 241 | 0.100 |
Why?
|
Skin Ulcer | 1 | 2013 | 130 | 0.100 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2024 | 2223 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2024 | 4014 | 0.100 |
Why?
|
Qualitative Research | 1 | 2022 | 3024 | 0.090 |
Why?
|
Hot Temperature | 1 | 2018 | 1434 | 0.090 |
Why?
|
Cholangiocarcinoma | 1 | 2017 | 554 | 0.090 |
Why?
|
Bile Duct Neoplasms | 1 | 2017 | 607 | 0.090 |
Why?
|
Disease Management | 2 | 2019 | 2507 | 0.090 |
Why?
|
Thalidomide | 1 | 2016 | 885 | 0.090 |
Why?
|
Drug Prescriptions | 1 | 2020 | 1668 | 0.090 |
Why?
|
Opportunistic Infections | 1 | 2014 | 376 | 0.090 |
Why?
|
Prognosis | 5 | 2019 | 29687 | 0.090 |
Why?
|
Methotrexate | 1 | 2017 | 1718 | 0.090 |
Why?
|
Aged, 80 and over | 5 | 2024 | 58952 | 0.090 |
Why?
|
Developing Countries | 1 | 2023 | 2863 | 0.090 |
Why?
|
Immunohistochemistry | 2 | 2014 | 11067 | 0.090 |
Why?
|
Nephrology | 1 | 2014 | 263 | 0.090 |
Why?
|
Melanocytes | 1 | 2013 | 509 | 0.090 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 1662 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2020 | 1789 | 0.080 |
Why?
|
Wound Healing | 1 | 2021 | 2800 | 0.080 |
Why?
|
Occupational Health | 1 | 2016 | 807 | 0.080 |
Why?
|
Hospitals, Veterans | 1 | 2012 | 395 | 0.080 |
Why?
|
Low Back Pain | 1 | 2018 | 983 | 0.080 |
Why?
|
Quality Improvement | 1 | 2024 | 3808 | 0.080 |
Why?
|
Decision Making | 1 | 2023 | 3931 | 0.080 |
Why?
|
Prostatic Neoplasms | 1 | 2012 | 11101 | 0.080 |
Why?
|
HIV Infections | 1 | 2015 | 17347 | 0.080 |
Why?
|
Gastroenterology | 1 | 2015 | 580 | 0.080 |
Why?
|
Kidney | 1 | 2024 | 7033 | 0.080 |
Why?
|
Pilot Projects | 2 | 2021 | 8642 | 0.080 |
Why?
|
Anxiety | 1 | 2023 | 4569 | 0.080 |
Why?
|
Brachytherapy | 1 | 2016 | 1223 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 1 | 2017 | 1878 | 0.080 |
Why?
|
Public Health | 1 | 2021 | 2672 | 0.070 |
Why?
|
Steroids | 1 | 2013 | 929 | 0.070 |
Why?
|
Pain | 1 | 2023 | 5072 | 0.070 |
Why?
|
Rheumatology | 1 | 2014 | 616 | 0.070 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5478 | 0.070 |
Why?
|
Education, Medical, Continuing | 1 | 2013 | 825 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2024 | 8998 | 0.070 |
Why?
|
Risk Factors | 5 | 2022 | 74239 | 0.070 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2015 | 955 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2021 | 5295 | 0.070 |
Why?
|
Gene Silencing | 1 | 2013 | 1495 | 0.070 |
Why?
|
History, 21st Century | 1 | 2013 | 1567 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11119 | 0.070 |
Why?
|
Cohort Studies | 2 | 2021 | 41496 | 0.070 |
Why?
|
Vitamin D Deficiency | 1 | 2017 | 1388 | 0.070 |
Why?
|
Prevalence | 1 | 2024 | 15721 | 0.070 |
Why?
|
Warfarin | 1 | 2015 | 1482 | 0.070 |
Why?
|
SEER Program | 1 | 2012 | 1453 | 0.070 |
Why?
|
Gastrointestinal Diseases | 1 | 2015 | 1201 | 0.070 |
Why?
|
Incidence | 4 | 2021 | 21365 | 0.070 |
Why?
|
Drug Approval | 1 | 2013 | 812 | 0.070 |
Why?
|
India | 1 | 2013 | 2287 | 0.070 |
Why?
|
Cultural Competency | 1 | 2009 | 298 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2813 | 0.060 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4851 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2024 | 20119 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 17897 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2015 | 1812 | 0.060 |
Why?
|
RNA Interference | 1 | 2013 | 2816 | 0.060 |
Why?
|
Stem Cell Transplantation | 1 | 2013 | 1600 | 0.060 |
Why?
|
Radiography | 1 | 2015 | 6974 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2017 | 4190 | 0.060 |
Why?
|
Propensity Score | 1 | 2012 | 1916 | 0.060 |
Why?
|
Radioimmunotherapy | 1 | 2024 | 90 | 0.060 |
Why?
|
Diet | 1 | 2022 | 8048 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9652 | 0.060 |
Why?
|
Patient-Centered Care | 1 | 2013 | 1427 | 0.050 |
Why?
|
Cytokines | 1 | 2018 | 7386 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7400 | 0.050 |
Why?
|
Hematologic Tests | 1 | 2024 | 239 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15841 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3461 | 0.050 |
Why?
|
Cardiology | 1 | 2014 | 1693 | 0.050 |
Why?
|
Primary Health Care | 1 | 2019 | 4678 | 0.050 |
Why?
|
Alleles | 1 | 2013 | 6857 | 0.050 |
Why?
|
MutS Homolog 2 Protein | 1 | 2023 | 197 | 0.050 |
Why?
|
Ultrasonography | 1 | 2015 | 5969 | 0.050 |
Why?
|
Patient Care Team | 1 | 2013 | 2515 | 0.050 |
Why?
|
Disease Progression | 2 | 2016 | 13511 | 0.050 |
Why?
|
Accreditation | 1 | 2024 | 473 | 0.050 |
Why?
|
Clindamycin | 1 | 2021 | 139 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2013 | 3048 | 0.050 |
Why?
|
Phenotype | 1 | 2019 | 16575 | 0.050 |
Why?
|
Arteriosclerosis | 1 | 2005 | 1056 | 0.040 |
Why?
|
Peer Review | 1 | 2022 | 217 | 0.040 |
Why?
|
Adolescent | 4 | 2021 | 88298 | 0.040 |
Why?
|
Publications | 1 | 2022 | 194 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2023 | 428 | 0.040 |
Why?
|
Anticoagulants | 1 | 2015 | 4795 | 0.040 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 3201 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2013 | 4320 | 0.040 |
Why?
|
Risk Assessment | 2 | 2017 | 24021 | 0.040 |
Why?
|
Animals | 3 | 2021 | 168079 | 0.040 |
Why?
|
Logistic Models | 1 | 2012 | 13249 | 0.030 |
Why?
|
Hospitalists | 1 | 2020 | 294 | 0.030 |
Why?
|
Advisory Committees | 1 | 2020 | 788 | 0.030 |
Why?
|
Self Efficacy | 1 | 2020 | 636 | 0.030 |
Why?
|
Hand | 1 | 2021 | 902 | 0.030 |
Why?
|
Registries | 1 | 2012 | 8247 | 0.030 |
Why?
|
Educational Measurement | 2 | 2015 | 1250 | 0.030 |
Why?
|
Trans-Activators | 1 | 2005 | 2846 | 0.030 |
Why?
|
Gender Identity | 1 | 2021 | 766 | 0.030 |
Why?
|
Signal Transduction | 1 | 2018 | 23416 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2014 | 39126 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2021 | 915 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 598 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1852 | 0.030 |
Why?
|
Pyrroles | 1 | 2021 | 1124 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 931 | 0.030 |
Why?
|
Boston | 2 | 2020 | 9327 | 0.030 |
Why?
|
Consensus | 1 | 2024 | 3134 | 0.030 |
Why?
|
Thigh | 1 | 2015 | 239 | 0.030 |
Why?
|
New England | 1 | 2017 | 1052 | 0.030 |
Why?
|
Whole-Body Irradiation | 1 | 2014 | 432 | 0.030 |
Why?
|
Rural Population | 1 | 2022 | 2277 | 0.020 |
Why?
|
Fingers | 1 | 2014 | 506 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 3245 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2631 | 0.020 |
Why?
|
Antifungal Agents | 1 | 2014 | 752 | 0.020 |
Why?
|
Triazoles | 1 | 2014 | 902 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2023 | 14675 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3923 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6417 | 0.020 |
Why?
|
Problem-Based Learning | 1 | 2009 | 356 | 0.020 |
Why?
|
Feedback | 1 | 2009 | 790 | 0.020 |
Why?
|
Learning | 1 | 2015 | 1737 | 0.020 |
Why?
|
Databases, Factual | 1 | 2021 | 7966 | 0.020 |
Why?
|
Umbilical Veins | 1 | 2005 | 423 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15308 | 0.010 |
Why?
|
Protective Agents | 1 | 2005 | 150 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2369 | 0.010 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2005 | 504 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10756 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12728 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36169 | 0.010 |
Why?
|
Kinetics | 1 | 2005 | 6312 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2005 | 12747 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2005 | 11856 | 0.000 |
Why?
|